DENND2B

Across TCGA pan-cancer cohorts, DENND2B RNA differs between tumor and matched normal tissue in 11 of 18 cancer types tested, making tumor–normal expression one of DENND2B’s most consistent transcriptional readouts.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where DENND2B RNA is repressed in tumor relative to normal tissue. In most cancer types DENND2B is over-expressed in tumor, although a few such as UCEC and BLCA show the opposite, repressed pattern.

UCEC, BLCA, and KIRC are the cancer types where DENND2B tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in DENND2B RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
UCEC	All	All	−2.495	<.001	8	view →
BLCA	Male	All	−1.556	<.001	8	view →
KIRC	Male	II,III,IV	−0.602	<.001	6	view →
CHOL	Female	All	+1.976	<.001	5	view →
LIHC	Female	All	+0.741	<.001	5	view →
COAD	All	All	−0.405	.004	5	view →
BRCA	Female	All	−0.531	<.001	4	view →
PRAD	All	All	−0.985	<.001	2	view →
READ	All	All	−0.783	.010	2	view →
STAD	Female	All	−0.770	.037	2	view →
KICH	Female	All	+0.517	.025	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 11 strongest of 11 lineages.

DENND2B–UCEC

Open the UCEC breakdown →